Differential effects of antibiotic therapy on the structure and function of human gut microbiota

PLoS One. 2013 Nov 25;8(11):e80201. doi: 10.1371/journal.pone.0080201. eCollection 2013.

Abstract

The human intestinal microbiota performs many essential functions for the host. Antimicrobial agents, such as antibiotics (AB), are also known to disturb microbial community equilibrium, thereby having an impact on human physiology. While an increasing number of studies investigate the effects of AB usage on changes in human gut microbiota biodiversity, its functional effects are still poorly understood. We performed a follow-up study to explore the effect of ABs with different modes of action on human gut microbiota composition and function. Four individuals were treated with different antibiotics and samples were taken before, during and after the AB course for all of them. Changes in the total and in the active (growing) microbiota as well as the functional changes were addressed by 16S rRNA gene and metagenomic 454-based pyrosequencing approaches. We have found that the class of antibiotic, particularly its antimicrobial effect and mode of action, played an important role in modulating the gut microbiota composition and function. Furthermore, analysis of the resistome suggested that oscillatory dynamics are not only due to antibiotic-target resistance, but also to fluctuations in the surviving bacterial community. Our results indicated that the effect of AB on the human gut microbiota relates to the interaction of several factors, principally the properties of the antimicrobial agent, and the structure, functions and resistance genes of the microbial community.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Biodiversity
  • Drug Resistance, Bacterial / drug effects
  • Follow-Up Studies
  • Gastrointestinal Tract / drug effects
  • Gastrointestinal Tract / microbiology
  • Humans
  • Metagenome
  • Microbiota / drug effects*
  • RNA, Ribosomal, 16S / genetics

Substances

  • Anti-Bacterial Agents
  • RNA, Ribosomal, 16S

Grants and funding

This work was supported by the Spanish Ministry of Economy and Competitiveness (BFU2008-04501-E/BMC, SAF2009-13032-C02-01 and SAF2012-31187) and by the ERA NET PathoGenoMics2 programme (0315441A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.